Retinal amyloid in Alzheimer's disease

JRCT ID: jRCTs061190024

Registered date:25/11/2019

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Alzheimer disease, mild cognitive impairment
• Date of first enrollment: 09/01/2020
• Target sample size: 60
• Study type: Interventional
• Intervention(s): Curcumin supplement (4g*2days)

Outcome(s)

• Primary Outcome: retinal amyloid deposition

Secondary Outcome

1. Background of participants
2. Cognitive function test
3. Brain MRI
4. Cerebral blood flow measured by SPECT
5. Amyloid PET
6. Adverse events
7. Compliance of curcumin

Key inclusion & exclusion criteria

• Age minimum: >= 65age old
• Age maximum: < 85age old
• Gender: Both

Include criteria

1. Outpatient of the neurology department of our clinic
2. Diagnosed as Alzheimer's disease, mild cognitive impairment(MCI), or normal cognitive function (except for complication of vascular dementia)
3. Native Japanese speaker
4. Age from 65 to 84

Exclude criteria

1. Impossible to take crucumin supplement due to severe dysphagia
2. Diagnosed as closed-angle glaucoma, and impossible to use mydriatic agent
3. Severe visual impairment requiring daily support
4. Unable to take curcumin supplement or examination due to severe cognitive decline
5. Judged by researchers not to be eligible

Related Information

• Primary Sponsor: Yamashita Toru